TENSILON Drug Patent Profile
✉ Email this page to a colleague
When do Tensilon patents expire, and what generic alternatives are available?
Tensilon is a drug marketed by Pai Holdings Pharm and is included in one NDA.
The generic ingredient in TENSILON is edrophonium chloride. There is one drug master file entry for this compound. Additional details are available on the edrophonium chloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TENSILON?
- What are the global sales for TENSILON?
- What is Average Wholesale Price for TENSILON?
Summary for TENSILON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 16 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,919 |
| DailyMed Link: | TENSILON at DailyMed |
Recent Clinical Trials for TENSILON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Diego | N/A |
US Patents and Regulatory Information for TENSILON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pai Holdings Pharm | TENSILON | edrophonium chloride | INJECTABLE;INJECTION | 007959-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pai Holdings Pharm | TENSILON PRESERVATIVE FREE | edrophonium chloride | INJECTABLE;INJECTION | 007959-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
